Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial

Jordana E Hoppe, Ajay S Kasi, Jessica E Pittman, Renee Jensen, Lena P Thia, Philip Robinson, Pornchai Tirakitsoontorn, Bonnie Ramsey, Marcus A Mall, Jennifer L Taylor-Cousar, Edward F McKone, Elizabeth Tullis, Danieli B Salinas, Jiaqiang Zhu, Yih-Chieh Chen, Violeta Rodriguez-Romero, Patrick R Sosnay, Gwyneth Davies, Gary McPhail, Karen McCoy, Erica Roesch, Daniel Weiner, Carlos Milla, Jessica Pittman, Rachel Linnemann, Anne Stone, Hugo Escobar, James Chmiel, Fadel Ruiz, Jonathan Gaffin, Hara Levy, Thomas Lahiri, Jordana Hoppe, Brooke Moore, Gwyneth Davies, Alexander Moeller, Anna-Maria Dittrich, Philipp Latzin, Pornchai Tirakitsoontorn, Maria Dowell, Lena Thia, Mirjam Stahl, Florian Stehling, Joan DeCelie-Germana, Isabelle Sermet-Gaudelus, Hettie Janssens, Philippe Reix, Philip Robinson, Claire Wainwright, Andrew Tai, Marcus Svedberg

Open source

DOI: 10.1016/s2213-2600(24)00407-7
Published: 2025-03
Container: The Lancet Respiratory Medicine
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2213-2600-24-00407-7,
  title = {Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial},
  author = {Jordana E Hoppe and Ajay S Kasi and Jessica E Pittman and Renee Jensen and Lena P Thia and Philip Robinson and Pornchai Tirakitsoontorn and Bonnie Ramsey and Marcus A Mall and Jennifer L Taylor-Cousar and Edward F McKone and Elizabeth Tullis and Danieli B Salinas and Jiaqiang Zhu and Yih-Chieh Chen and Violeta Rodriguez-Romero and Patrick R Sosnay and Gwyneth Davies and Gary McPhail and Karen McCoy and Erica Roesch and Daniel Weiner and Carlos Milla and Jessica Pittman and Rachel Linnemann and Anne Stone and Hugo Escobar and James Chmiel and Fadel Ruiz and Jonathan Gaffin and Hara Levy and Thomas Lahiri and Jordana Hoppe and Brooke Moore and Gwyneth Davies and Alexander Moeller and Anna-Maria Dittrich and Philipp Latzin and Pornchai Tirakitsoontorn and Maria Dowell and Lena Thia and Mirjam Stahl and Florian Stehling and Joan DeCelie-Germana and Isabelle Sermet-Gaudelus and Hettie Janssens and Philippe Reix and Philip Robinson and Claire Wainwright and Andrew Tai and Marcus Svedberg},
  year = {2025},
  journal = {The Lancet Respiratory Medicine},
  doi = {10.1016/s2213-2600(24)00407-7},
  url = {https://doi.org/10.1016/s2213-2600(24)00407-7}
}

RIS

TY  - JOUR
TI  - Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
AU  - Jordana E Hoppe
AU  - Ajay S Kasi
AU  - Jessica E Pittman
AU  - Renee Jensen
AU  - Lena P Thia
AU  - Philip Robinson
AU  - Pornchai Tirakitsoontorn
AU  - Bonnie Ramsey
AU  - Marcus A Mall
AU  - Jennifer L Taylor-Cousar
AU  - Edward F McKone
AU  - Elizabeth Tullis
AU  - Danieli B Salinas
AU  - Jiaqiang Zhu
AU  - Yih-Chieh Chen
AU  - Violeta Rodriguez-Romero
AU  - Patrick R Sosnay
AU  - Gwyneth Davies
AU  - Gary McPhail
AU  - Karen McCoy
AU  - Erica Roesch
AU  - Daniel Weiner
AU  - Carlos Milla
AU  - Jessica Pittman
AU  - Rachel Linnemann
AU  - Anne Stone
AU  - Hugo Escobar
AU  - James Chmiel
AU  - Fadel Ruiz
AU  - Jonathan Gaffin
AU  - Hara Levy
AU  - Thomas Lahiri
AU  - Jordana Hoppe
AU  - Brooke Moore
AU  - Gwyneth Davies
AU  - Alexander Moeller
AU  - Anna-Maria Dittrich
AU  - Philipp Latzin
AU  - Pornchai Tirakitsoontorn
AU  - Maria Dowell
AU  - Lena Thia
AU  - Mirjam Stahl
AU  - Florian Stehling
AU  - Joan DeCelie-Germana
AU  - Isabelle Sermet-Gaudelus
AU  - Hettie Janssens
AU  - Philippe Reix
AU  - Philip Robinson
AU  - Claire Wainwright
AU  - Andrew Tai
AU  - Marcus Svedberg
PY  - 2025
JO  - The Lancet Respiratory Medicine
DO  - 10.1016/s2213-2600(24)00407-7
UR  - https://doi.org/10.1016/s2213-2600(24)00407-7
ER  -

APA

Hoppe, J. E., Kasi, A. S., Pittman, J. E., Jensen, R., Thia, L. P., Robinson, P., Tirakitsoontorn, P., Ramsey, B., Mall, M. A., Taylor-Cousar, J. L., McKone, E. F., Tullis, E., Salinas, D. B., Zhu, J., Chen, Y., Rodriguez-Romero, V., Sosnay, P. R., Davies, G., McPhail, G., McCoy, K., Roesch, E., Weiner, D., Milla, C., Pittman, J., Linnemann, R., Stone, A., Escobar, H., Chmiel, J., Ruiz, F., Gaffin, J., Levy, H., Lahiri, T., Hoppe, J., Moore, B., Davies, G., Moeller, A., Dittrich, A., Latzin, P., Tirakitsoontorn, P., Dowell, M., Thia, L., Stahl, M., Stehling, F., DeCelie-Germana, J., Sermet-Gaudelus, I., Janssens, H., Reix, P., Robinson, P., Wainwright, C., Tai, A., & Svedberg, M. (2025). Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(24)00407-7

Source records

crossref · retrieved 2026-09-26T14:37:58.262Z